Northern India Herald

Xerostomia Market to Observe Impressive Growth by (2022-2032), Evaluates DelveInsight | Key Companies – Lubris BioPharma, MeiraGTx

 Breaking News
  • No posts were found

Xerostomia Market to Observe Impressive Growth by (2022-2032), Evaluates DelveInsight | Key Companies – Lubris BioPharma, MeiraGTx

January 19
21:21 2023
Xerostomia Market to Observe Impressive Growth by (2022-2032), Evaluates DelveInsight | Key Companies -  Lubris BioPharma, MeiraGTx
The Xerostomia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Xerostomia pipeline products will significantly revolutionize the Xerostomia market dynamics.

DelveInsight’s “Xerostomia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Xerostomia, historical and forecasted epidemiology as well as the Xerostomia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


The Xerostomia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 


To Know in detail about the Xerostomia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Xerostomia Market Insights


Xerostomia Overview

Xerostomia is defined as the “complaint of oral dryness”. It can occur due to inadequate salivary secretion secondary to abnormal function of the salivary glands, which is categorized as “true” xerostomia; however, most patients with xerostomia often do not have objective signs of hyposalivation. “Symptomatic” xerostomia or “pseudo” xerostomia refers to oral dryness despite normal salivary gland function.


Some of the key facts of the Xerostomia Market Report: 

  • The Xerostomia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • According to the European Association of Oral Medicines, Xerostomia is the subjective complaint of oral dryness, and is medically classified as a symptom. It is especially frequent in the elderly and has been reported to occur in 17 to 39% of the persons aged 65 years or more.
  • According to the results published by Rech et al., the prevalence of xerostomia, of low stimulated salivary flow rate and low at rest salivary flow rate were 338 (38.8%), 494 (56.6%), 320 (36.7%), respectively. And important portion of the sample con ‐ currently presented xerostomia and salivary hypofunction (22.4%; n = 173)
  • According to the study carried out by Hahnel et al. in Germany prevalence of xerostomia was 16% (patients with XI scores 10) and prevalence of hyposalivation was 31% (patients with stimulated salivary flow rate 0.7 ml/min)
  • Key Xerostomia Companies: Lubris BioPharma, MeiraGTx, and others
  • Key Xerostomia Therapies: LBS020, AAV2hAQP1, and others
  • The Xerostomia epidemiology based on gender analyzed that Xerostomia occurs more commonly in females than males


Get a Free sample for the Xerostomia Market Report –


Key benefits of the Xerostomia Market report:

  1. Xerostomia market report covers a descriptive overview and comprehensive insight of the Xerostomia Epidemiology and Xerostomia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Xerostomia market report provides insights on the current and emerging therapies.
  3. Xerostomia market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Xerostomia market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Xerostomia market.


Download the report to understand which factors are driving Xerostomia epidemiology trends @ Xerostomia Epidemiological Insights 


Xerostomia Market  

The dynamics of the Xerostomia market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 


Xerostomia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.


Xerostomia Epidemiology Segmentation:

The Xerostomia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Xerostomia
  • Prevalent Cases of Xerostomia by severity
  • Gender-specific Prevalence of Xerostomia
  • Diagnosed Cases of Episodic and Chronic Xerostomia


Xerostomia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Xerostomia market or expected to get launched during the study period. The analysis covers Xerostomia market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Xerostomia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.


Discover more about therapies set to grab major Xerostomia market share @ Xerostomia market forecast 


Xerostomia Therapies and Key Companies

  • LBS020: Lubris BioPharma
  • AAV2hAQP1: MeiraGTx


Scope of the Xerostomia Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Xerostomia Companies: Lubris BioPharma, MeiraGTx, and others
  • Key Xerostomia Therapies: LBS020, AAV2hAQP1, and others
  • Xerostomia Therapeutic Assessment: Xerostomia current marketed and Xerostomia emerging therapies
  • Xerostomia Market Dynamics: Xerostomia market drivers and Xerostomia market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Xerostomia Unmet Needs, KOL’s views, Analyst’s views, Xerostomia Market Access and Reimbursement 


Table of Contents 

1. Xerostomia Market Report Introduction

2. Executive Summary for Xerostomia

3. SWOT analysis of Xerostomia

4. Xerostomia Patient Share (%) Overview at a Glance

5. Xerostomia Market Overview at a Glance

6. Xerostomia Disease Background and Overview

7. Xerostomia Epidemiology and Patient Population

8. Country-Specific Patient Population of Xerostomia 

9. Xerostomia Current Treatment and Medical Practices

10. Xerostomia Unmet Needs

11. Xerostomia Emerging Therapies

12. Xerostomia Market Outlook

13. Country-Wise Xerostomia Market Analysis (2019–2032)

14. Xerostomia Market Access and Reimbursement of Therapies

15. Xerostomia Market Drivers

16. Xerostomia Market Barriers

17.  Xerostomia Appendix

18. Xerostomia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight


To know more about Xerostomia treatment, visit @ Xerostomia Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States